Glycom is the world's leading supplier in the Human Milk Oligosaccharides (HMO) market and the only fully integrated HMO player with its own product development, preclinical and clinical development, regulatory and large-scale production. This allows us to make HMOs easily available for you. GlyCare™ HMOs are used globally as a key ingredient in infant nutrition, children and adult supplements and foods.
Created by nature. Brought to you by Glycom.
HMOs are complex carbohydrates that exist naturally in large quantities in our very first food, mother's milk. Naturally occurring, there are about 200 different ones and they have evolved over millions of years providing us with a unique nutrient. At Glycom we have a deep understanding of HMOs and their impact on the human body. All our HMOs have been clinically tested in infants, children and adults and have proven to be safe and beneficial.
Science and technology is at the heart of all we do
Driving HMO innovation is our business. Leading preclinical and clinical research through our internal R&D and extensive network of partners and thought leaders globally.
Suffering from constipation, diarrhea, stomach pain or bloating?
Holigos® IBS is clinically proven to provide relief from Irritable Bowel Syndrome (IBS).
Up to 15% of the global population suffers from IBS. Glycom recently launched Holigos® IBS, a medical food for the dietary management of IBS - currently available in the US.
Glycom is a Danish biotechnology company dedicated to the scientific, clinical and commercial development of Human Milk Oligosaccharides for a broad range of applications. Our first focus is making Human Milk Oligosaccharides (HMOs) widely available for human consumption. HMOs are unique microbiome nutrients natural to the human body as they are identical in structure to those present in mother’s milk and similar to those in the protective lining of the digestive tract. At Glycom, we have cracked the code of manufacturing these unique compounds, which are authorized as safe by EFSA and FDA.Read more